IP Library Granted Patent US 9,562,015
Granted Patent B2
US 9,562,015 · App. 14/359,146 · Granted Feb 7, 2017

Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations

Inventors: Uday B. Kompella (Englewood, CO); Ashish Thakur (Cincinnati, OH)
Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
C07D231/12A61K31/415A61K31/58C07D498/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,562,015
App. No.
14/359,146
Granted
Feb 7, 2017
Kind
B2
Abstract

The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.

Claims (9)

1. A compound comprising, celecoxib having the formula:

wherein the terminal functional group —SO 2 NH 2 is masked by binding to a multi-functional counter acid linking group, the linking group further having a taurine bound thereto.

2. The compound of claim 1 wherein the multi-functional counter acid group is selected from the group consisting of a maleate, a fumarate, a tartrate, a citrate and a succinate.

3. The compound of claim 2 , wherein the multi-functional counter acid group is a succinate.

4. A composition comprising the compound of claim 1 and a pharmaceutical carrier, diluent, excipient, or a combination thereof.

5. A method of treating an ocular disease comprising administering to a patient in need thereof the composition of claim 4 , wherein administration results in delivery of the composition to posterior or anterior segment tissues of the eye including retina, choroid, vitreous humor, iris, ciliary body, aqueous humor or other eye tissues.

6. The method of claim 5 , wherein the composition is administered topically to the eye.

7. The method of claim 5 , wherein the ocular disease is an ocular degenerative disease, an ocular vascular disease, an ocular inflammatory disease, an ocular infectious disease, glaucoma, or optic neuritis.

8. The method of claim 7 , wherein the disease is diabetic retinopathy.

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 29, 2014
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033841/0321 →
Continuity (2)
Provisional Application 61561256 · Nov 17, 2011
Related Publication 20140309200A1 · Oct 16, 2014